Navigation Links
15-Minute Data From Phase 3 Study of Avanafil Featured as a Late Breaking Abstract at SMSNA Annual Meeting
Date:11/14/2011

reliance on third parties; failure to continue to develop innovative investigational drug candidates and drugs; risks related to the failure to obtain FDA or foreign authority clearances or approvals and noncompliance with FDA regulations; our ability to demonstrate through clinical testing the safety and effectiveness of our investigational drug candidates; our dependence on the performance of our collaborative partners; the timing of initiation and completion of clinical trials and submissions to the FDA or foreign authorities; the volatility and liquidity of the financial markets; our liquidity and capital resources; and our expected future revenues, operations and expenditures.  As with any pharmaceutical in development, there are significant risks in the development, the regulatory approval, and commercialization of new products. There are no guarantees that our response to the FDA's CRL or CHMP's 120-day questions, the FDA's requests stemming from the end-of-review meeting or the results of the retrospective observational study of fetal outcomes in infants born to mothers exposed to topiramate during pregnancy and subsequent meetings and communications will be sufficient to satisfy the FDA or CHMP's safety concerns, that the FDA or foreign authorities will not require us to conduct any additional prospective studies or retrospective observational studies, or that any product will receive regulatory approval for any indication or prove to be commercially successful.  VIVUS does not undertake an obligation to update or revise any forward-looking statements.  Investors should read the risk factors set forth in VIVUS' Form 10-K for the year ending December 31, 2010, and periodic reports filed with the Securities and Exchange Commission.CONTACT:VIVUS, Inc.Investor Relations:The Trout GroupTimothy E. MorrisBrian KorbChief Financial Officer646-378-2923650-934-5200
'/>"/>
SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
2. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
3. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
4. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
5. Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug
6. PTC124 Shows Promising Activity in Cystic Fibrosis; Phase 2 Proof-of-Concept Data Published in the Lancet
7. NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients
8. Michigan Innovation Equipment Depot Launches Next Phase of Distribution
9. Phase 1b/2a Program Commences for RVX-208
10. Chiltern Early Phase: Fully Integrated and Business Ready
11. Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2014)... 2014 Deep Research Report on ... and in-depth research report on the China Linalool ... including its definition, classification, application, and industry chain ... covers the international market analysis, including China’s domestic ... macroeconomic environment & economic situation analysis. The report ...
(Date:8/18/2014)... Aug. 18, 2014 BioElectronics Corporation ... consumer medical devices said that its EVP ... by CEOLIVE.TV as part of its Executive ... is available at http://ceolive.tv/bioelectronics-corp-otc-biel/biel-videos/2282-ceolive-tv-interview-bioelectronics-corp-otcqb-biel ... to investors the unique advantages of BioElectronics ...
(Date:8/18/2014)... Global HIV Infection Drug Market and Pipeline Insight ... of HIV infection and the number of deaths due to ... rate across the globe. It has been estimated that the ... in 2013, with the rates for children being even much ... infection rates has been the improved access to antiretroviral drugs ...
(Date:8/18/2014)... , Aug. 18, 2014 TNI BioTech, Inc. ... pioneering the manufacturing and marketing of innovative therapies for ... Company is providing a second notice of TNI BioTech,s ... making the announcement, Noreen Griffin , founder and ... advance for your participation in the Annual Meeting. On ...
Breaking Biology Technology:Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 2Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 3Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 4BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 2BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 3Global HIV Infection Drug Market Overview 2Global HIV Infection Drug Market Overview 3Global HIV Infection Drug Market Overview 4TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 2TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 3TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 4
... EDEN PRAIRIE, Minn., Oct. 7 ACIST Medical ... new 75,000 square foot,expanded corporate Headquarters and manufacturing ... Pawlenty and Eden Prairie Mayor Phil Young will,join ... for a ribbon cutting,ceremony at the company,s new ...
... Roche Diagnostics Makes List for Fourth Consecutive ... ranked Roche,Diagnostics as one of the magazine,s ... bestowed to only a handful of companies ... Diagnostics, which ranked No. 86, in the ...
... Oct. 7 /Xinhua-PRNewswire-FirstCall/ -- Huifeng Bio-,Pharmaceutical Technology, Inc. ... and producer of plant extracts and pharmaceutical raw,materials ... in,Xi,an, China, is pleased to announce the signing ... Xintong Medical Ltd ("Qinba"). On,Sept 5, 2008 the ...
Cached Biology Technology:ACIST Medical Systems Announces the Opening of Its New Expanded Corporate Headquarters in Eden Prairie, MN 2ACIST Medical Systems Announces the Opening of Its New Expanded Corporate Headquarters in Eden Prairie, MN 3InformationWeek Puts Roche Diagnostics on Top 500 Innovative Tech Users List 2Huifeng Bio-Pharmaceutical (HFGB) Signs Exclusive Management Operating Agreement with Xi'an Qinba Xintong Medical Ltd.; HFGB to Retain Up to 70% of Qinba's Total Profit 2
(Date:8/19/2014)... week,s Eos: Long-Term Ecological Research and Network-Level Science, , ... a wide range of ecosystems was responding to global ... particularly powerful if it coupled multiple decades of information ... experiments and models from dozens of different ecosystem types. ... the Long-Term Ecological Research (LTER) Network, which will soon ...
(Date:8/19/2014)... MIT chemical engineers have devised a new implantable tissue ... slowly over a few weeks. When applied to bone ... to rapidly form new bone that looks and behaves ... coated scaffold could offer a dramatic improvement over the ... bone from another part of the patient,s body ...
(Date:8/19/2014)... during warm phases and became extinct during cold phases, ... link between marine crocodilian diversity and the evolution of ... million years. , The research, led by Dr ... formerly from the University of Bristol, UK is published ... are ,cold-blooded, animals that mainly live in fresh waters ...
Breaking Biology News(10 mins):This week from AGU: Long-term ecological research, predicting cholera outbreaks 2Engineering new bone growth 2Engineering new bone growth 3Evolution of marine crocodilians constrained by ocean temperatures 2
... a new method -- "inverse Partial Fluorescence Yield" (iPFY) ... the electronic structure of liquids free of sample damages. ... LiXEdrom experimental chamber, where a fluid stream of micrometer ... irradiated with X-ray radiation. These kinds of experiments ...
... a recent expedition to the inhospitable North Atlantic Ocean, scientists ... growth of tiny plants were stumped to discover that the ... to offer the light they need for their growth spurt. ... longer days and calmer seas that force phytoplankton near the ...
... JUPITER, FL, July 5, 2012 Scientists from the Florida ... of intricate biochemical steps that lead to the successful production ... The study, which appears in the July 6, 2012 ... the assembly of a structure called the ribosome, a large ...
Cached Biology News:Aqueous iron interacts as strong as solid iron 2Eddies, not sunlight, spur annual bloom of tiny plants in North Atlantic 2Eddies, not sunlight, spur annual bloom of tiny plants in North Atlantic 3Scripps Florida scientists identify critical 'quality control' for cell growth 2
in vitro Translation, Accessory Products...
... (serial analysis of gene expression) ... analysis. Expression profiles generated by ... detect low-abundance transcripts making it ... The I-SAGE Kit is designed ...
Sheep Serum US Origin...
... and flexibility press-to-seal silicone isolators can be ... researcher. They are available either pre-cut to ... that can be easily trimmed to prepare ... non-cytotoxic and can be used to isolate ...
Biology Products: